Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Urogynecology Journal
Erschienen in: International Urogynecology Journal 10/2010

01.10.2010 | Review

Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review

verfasst von: Sahithi Tirumuru, Deyaa Al-Kurdi, Pallavi Latthe

Erschienen in: International Urogynecology Journal | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Intravesical botulinum toxin A (BTX-A) is emerging as a potential new treatment for refractory interstitial cystitis (IC). However, there has been conflicting evidence on this treatment's effectiveness. The aim of our systematic review was to assess the effectiveness and adverse effects of intravesical BTX-A in IC.

Methods

Randomised controlled trials (RCTs) and prospective studies of relevance were identified, assessed for inclusion and then analysed by two independent reviewers.

Results

Ten (three RCTs and seven prospective cohort) studies with a total of 260 participants were included. Eight studies reported improvement in symptoms. Urodynamic parameters were variable. Meta-analysis was not performed due to heterogeneity in reporting of outcomes. Some adverse events, e.g. dysuria and voiding difficulty, were noted (19 out of 260 were required to self-catheterise at anytime postoperatively).

Conclusions

The evidence from the studies thus far suggests a trend towards short-term benefit with intravesical BTX-A injections in refractory IC, but further robust evidence should be awaited.
Literatur
1.
Van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60–67CrossRefPubMed
2.
Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T et al (2010) Bladder pain syndrome committee of the international consultation on incontinence. Neurourol Urodyn 29(1):191–198CrossRefPubMed
3.
Gillenwater JY, Wein AJ (1988) Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J Urol 140:203–206PubMed
4.
Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LM Jr, McKinlay JB (2007) Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol 177:1390–1394CrossRefPubMed
5.
Held PJ, Hanno PM, Wein AJ, Pauly MV, Cahn MA (1990) Epidemiology of interstitial cystitis. In: Hanno PM, Staskin DR, Krane RJ, Wein AJ (eds) Interstitial cystitis. Springer, London, pp 29–48
6.
Rovner E, Propert KJ, Brensinger C, Wein AJ, Foy M, Kirkemo A et al (2000) Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 56:940–945CrossRefPubMed
7.
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin A has antinociceptive effects in treating Interstitial cystitis. Urology 64:871–875CrossRefPubMed
8.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al (2000) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Proceedings of the Third Symposium on Systematic Reviews: Behind the Basics, Oxford, England, 4–9 July (Ref Type: Electronic Citation)
9.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMed
10.
Kuo HC (2005) Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urol Int 75:170–174CrossRefPubMed
11.
Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 104:657–661CrossRefPubMed
12.
Carl S, Grosse J, Laschke S (2007) Treatment of interstitial cystitis with botulinum toxin type A. Eur Urol 6:248
13.
Pinto RA, Silva A, Lopes T et al (2009) Intra-trigonal injection of botulinum toxin A in patients with bladder pain syndrome-results at 9 months follow up. J Urol 181(4, supplement):20, Ref Type: AbstractCrossRef
14.
Davies A, Chahal R, Inman R, Urwin G (2006) Intravesical botulinum A toxin (Botox)—does it have a role in the management of interstitial cystitis. Eur Urol Suppl 5(supplements 2):22, Ref Type: Abstract
15.
El-Bahnasy A, Farahat YA, El-Bendary M, Taha MR, El- Damhogy M, Sherif Mourad (2009) A randomized controlled trial of bacillus Calmette–Guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis. UroToday International Journal 2. doi:10.​3834/​uij.​1944-5784.​2008.​12.​06 (Ref Type: Electronic Citation)
16.
Manning JA, Dwyer P, Rosamilia A, Murrary C, Thomas E, Beattie K (2009) Prospective randomised double blind study of the effectiveness of botulinum A toxin for treatment of refractory painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 20(suppl 2):S87–S88, Ref Type: Abstract
17.
Ramsay AK, Small DR, Conn IG (2007) Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon 5:331–333CrossRefPubMed
18.
Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 179:1031–1034CrossRefPubMed
19.
Giannantoni A, Costantini E, De Stasi S, Mearini E, Santaniello F, Vianello A et al (2007) Intravesical passive delivery of botulinum A toxin in patients affected by painful bladder syndrome: a pilot study. Eur Urol 6(supplements 2):246, Ref Type: Abstract
20.
Liu HT, Kuo HC (2007) Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70:463–468CrossRefPubMed
21.
Chuang YC, Kim DK, Chiang PH, Chancellor MB (2008) Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. BJU Int 102:704–706CrossRefPubMed
22.
Tara Frenkl L, Raymond R (2005) Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin N Am 32:89–99CrossRef
23.
Miller JL (2009) Botox as a treatment for interstitial cystitis in women: a randomized placebo controlled trial. University of Washington, Seattle (Ref Type: Electronic Citation)
24.
Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn 28(4):274–286, Ref Type: AbstractCrossRefPubMed
Metadaten
Titel
Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review
verfasst von
Sahithi Tirumuru
Deyaa Al-Kurdi
Pallavi Latthe
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 10/2010
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-010-1162-9

Weitere Artikel der Ausgabe 10/2010

International Urogynecology Journal 10/2010 Zur Ausgabe

Original Article

Preoperative Valsalva voiding increases the risk of urinary retention after midurethral sling placement

Original Article

Evaluation of safety and feasibility of ambulatory urogynaecological procedures in a 24-h setting

Original Article

Efficacy and safety of TVT-O and TVT-Secur in the treatment of female stress urinary incontinence: 1-year follow-up

Letter to the Editor

Long-term lower urinary tract dysfunction after radical hysterectomy in patients with early postoperative voiding dysfunction: reply to comments by Sansone et al.

Original Article

The Hordaland women’s cohort: prevalence, incidence, and remission of urinary incontinence in middle-aged women

Original Article

Do repetitive Valsalva maneuvers change maximum prolapse on dynamic MRI?

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise